[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX354450B - Anticuerpos anti proteína accesoria del receptor de interleucina-1 y su uso para tratamiento en humanos. - Google Patents

Anticuerpos anti proteína accesoria del receptor de interleucina-1 y su uso para tratamiento en humanos.

Info

Publication number
MX354450B
MX354450B MX2013008375A MX2013008375A MX354450B MX 354450 B MX354450 B MX 354450B MX 2013008375 A MX2013008375 A MX 2013008375A MX 2013008375 A MX2013008375 A MX 2013008375A MX 354450 B MX354450 B MX 354450B
Authority
MX
Mexico
Prior art keywords
il1rap
treating human
interleukin
specificity
agents
Prior art date
Application number
MX2013008375A
Other languages
English (en)
Other versions
MX2013008375A (es
Inventor
Thoas Fioretos
Marcus Järås
Original Assignee
Cantargia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45755402&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX354450(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cantargia Ab filed Critical Cantargia Ab
Publication of MX2013008375A publication Critical patent/MX2013008375A/es
Publication of MX354450B publication Critical patent/MX354450B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • C07K16/245IL-1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/1033Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for cytokines, lymphokines or interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061Blood cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a un agente que comprende o consiste de un anticuerpo o un fragmento de unión a antígeno del mismo con especificidad para la proteína accesoria del receptor de interleucina-1 (IL1RAP) para usarse en el tratamiento o prevención de un tumor sólido en un paciente, en donde el tumor sólido comprende células que expresan IL1RAP, y en donde el agente induce muerte celular y/o inhibe el crecimiento y/o proliferación de células asociadas con el tumor sólido.
MX2013008375A 2011-01-19 2012-01-19 Anticuerpos anti proteína accesoria del receptor de interleucina-1 y su uso para tratamiento en humanos. MX354450B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161434040P 2011-01-19 2011-01-19
PCT/GB2012/050120 WO2012098407A1 (en) 2011-01-19 2012-01-19 Anti - il1rap antibodies and their use for treating human

Publications (2)

Publication Number Publication Date
MX2013008375A MX2013008375A (es) 2013-08-12
MX354450B true MX354450B (es) 2018-03-05

Family

ID=45755402

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013008375A MX354450B (es) 2011-01-19 2012-01-19 Anticuerpos anti proteína accesoria del receptor de interleucina-1 y su uso para tratamiento en humanos.

Country Status (14)

Country Link
US (4) US9403906B2 (es)
EP (3) EP2665749B1 (es)
JP (1) JP5940093B2 (es)
KR (1) KR101989134B1 (es)
CN (2) CN103459424B (es)
AU (1) AU2012208379B2 (es)
BR (1) BR112013018399B1 (es)
CA (1) CA2824719C (es)
DK (2) DK3020730T3 (es)
ES (2) ES2566538T3 (es)
MX (1) MX354450B (es)
PL (2) PL3020730T3 (es)
RU (1) RU2597831C2 (es)
WO (1) WO2012098407A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009120903A2 (en) 2008-03-26 2009-10-01 Cellerant Therapeutics, Inc. Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof
GB2472856B (en) 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
ES2566538T3 (es) 2011-01-19 2016-04-13 Cantargia Ab Anticuerpos anti-IL1RAP y su uso para el tratamiento de tumores sólidos
US9765148B2 (en) 2011-03-16 2017-09-19 Argen-X N.V. Antibodies to CD70
US9873918B2 (en) 2011-08-11 2018-01-23 Albert Einstein College Of Medicine, Inc. Treatment of acute myeloid leukemia and myelodysplastic syndromes
KR20240042192A (ko) 2013-12-17 2024-04-01 크링 바이오테라퓨틱스 비.브이. 골수 증식성 또는 림프 증식성 질환에 대응하는 수단 및 방법
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
GB201413913D0 (en) 2014-08-06 2014-09-17 Cantargia Ab Novel antibodies and uses thereof
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
WO2016085832A1 (en) * 2014-11-24 2016-06-02 Albert Einstein College Of Medicine, Inc. Peptides for blocking il1rap protein-protein interaction and uses thereof for treatment of disease
EP3313887A2 (en) 2015-06-26 2018-05-02 MAB Discovery GmbH Monoclonal anti-il-1racp antibodies
MA43164A (fr) * 2015-11-02 2018-09-12 Janssen Pharmaceutica Nv Anticorps anti-il1rap, molécules bispécifiques de liaison à un antigène liant il1rap et cd3 et leurs utilisations
EP3241845A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanized anti-il-1r3 antibodies
AU2017343784A1 (en) * 2016-10-16 2019-08-29 Cantargia Ab Anti-IL1-RAP antibodies
JP7105235B2 (ja) 2016-12-01 2022-07-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 免疫petイメージングのための放射性標識された抗pd-l1抗体
US10067409B2 (en) 2017-02-02 2018-09-04 James Harrison Elias Camera supporting base
EP3401332A1 (en) * 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
KR102714600B1 (ko) * 2017-05-16 2024-10-08 비온디스 비.브이. 항-SIRPα 항체
USD951260S1 (en) 2017-05-19 2022-05-10 James Harrison Elias Electronic device mount
US11162632B2 (en) 2017-06-02 2021-11-02 James Harrison Elias Tripod stabilizing base
CA3066918A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
JP2020533960A (ja) 2017-08-01 2020-11-26 シティ・オブ・ホープCity of Hope 抗il1rap抗体
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
TW202021618A (zh) 2018-08-17 2020-06-16 美商23與我有限公司 抗il1rap抗體及其使用方法
USD897414S1 (en) 2018-11-29 2020-09-29 James Harrison Elias Tripod mount
USD888142S1 (en) 2018-11-29 2020-06-23 James Harrison Elias Tripod mount
USD896878S1 (en) 2018-11-29 2020-09-22 James Harrison Elias Tripod mount
USD888815S1 (en) 2018-11-29 2020-06-30 James Harrison Elias Tripod mount
USD888139S1 (en) 2018-11-29 2020-06-23 James Harrison Elias Tripod mount
USD900201S1 (en) 2018-11-29 2020-10-27 James Harrison Elias Tripod mount
USD888140S1 (en) 2018-11-29 2020-06-23 James Harrison Elias Tripod mount
USD888141S1 (en) 2018-11-29 2020-06-23 James Harrison Elias Tripod mount
USD888816S1 (en) 2018-11-30 2020-06-30 James Harrison Elias Tripod mount
USD888817S1 (en) 2018-11-30 2020-06-30 James Harrison Elias Tripod mount
USD896879S1 (en) 2018-11-30 2020-09-22 James Harrison Elias Tripod mount
USD896880S1 (en) 2018-11-30 2020-09-22 James Harrison Elias Tripod mount
TWI848030B (zh) 2018-12-18 2024-07-11 比利時商阿根思公司 Cd70組合治療
KR20220026585A (ko) 2019-06-26 2022-03-04 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Il1rap 결합 단백질
EP4013794A4 (en) * 2019-08-12 2023-11-22 City of Hope ANTI-IL1RAP ANTIBODIES
MX2023002901A (es) 2020-09-14 2023-06-01 Ichnos Sciences SA Anticuerpos que se unen a la proteína auxiliar del receptor de interleucina-1 (il1rap) y usos de estos.
AU2021405730A1 (en) 2020-12-23 2023-07-06 Cantargia Ab Anti-il1rap antibody
CN114736885A (zh) * 2022-05-27 2022-07-12 四川大学华西医院 一种携带bcr-abl1基因激酶区双位点突变的细胞株及其构建方法
US12054552B2 (en) 2022-09-21 2024-08-06 Sanofi Biotechnology Humanized anti-IL-1R3 antibody and methods of use

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
US5094941A (en) * 1987-12-31 1992-03-10 Zymogenetics, Inc. Monoclonal antibodies to PDGF
CA1329119C (en) * 1988-03-29 1994-05-03 Milton David Goldenberg Cytotoxic therapy
US5120525A (en) * 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9314623D0 (en) * 1993-07-14 1993-08-25 Nordion Int Inc Localization and therapy with agents directed against prostate specific antigen in breast cancer
PE64396A1 (es) * 1995-01-23 1997-01-28 Hoffmann La Roche Proteina accesoria del receptor de la interleucina 1
CN1169754A (zh) * 1995-01-23 1998-01-07 霍夫曼-拉罗奇有限公司 人白介素-1受体辅助蛋白
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
US6280955B1 (en) 1997-12-16 2001-08-28 Tularik Inc. Interleukin-1 receptor accessory proteins, nucleic acids and methods
US20030215453A1 (en) 2002-05-14 2003-11-20 Dedera Douglas A. Methods of therapy and diagnosis using immunotargeting of cells expressing VpreB1 protein
US20030026806A1 (en) 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US7049095B2 (en) 2000-10-31 2006-05-23 Immunex Corporation DNA encoding IL-1 receptor accessory protein
PL374118A1 (en) 2001-08-07 2005-10-03 Immunex Corporation Interleukin-1 receptors in the treatment of diseases
WO2004100987A2 (en) 2003-05-06 2004-11-25 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat neointimal hyperplasia
CN1852974A (zh) * 2003-06-09 2006-10-25 密歇根大学董事会 用于治疗和诊断癌症的组合物和方法
US20060019256A1 (en) 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
BRPI0607753A2 (pt) 2005-02-16 2009-10-06 Wyeth Corp método para prever um efeito clìnico em resposta a um tratamento de uma leucemia; método para prever um efeito clìnico de uma leucemia; método para selecionar um tratamento para um paciente com leucemia; método para o diagnóstico ou monitoramento de ocorrência, desenvolvimento, progressão ou tratamento de uma leucemia; arranjo para uso num método para prever um efeito clìnico para um paciente aml; arranjo para uso num método de diagnóstico de aml; meio legìvel por computador; kit para o prognóstico de aml
WO2006110593A2 (en) 2005-04-07 2006-10-19 Macrogenics, Inc. Biological targets for the diagnosis, treatment and prevention of cancer
WO2007024715A2 (en) * 2005-08-19 2007-03-01 Abbott Laboratories Dual variable domain immunoglobin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
US20090324618A1 (en) 2006-03-24 2009-12-31 Armstrong Scott A Novel signature self renewal gene expression programs
US8207304B2 (en) 2006-10-19 2012-06-26 Csl Limited Antibody antagonists of interleukin-13 receptor α1
SI4160212T1 (sl) 2008-01-15 2024-06-28 The Board Of Trustees Of The Leland Stanford Junior University Označevalci matičnih celic akutne mieloične levkemije
WO2009120903A2 (en) 2008-03-26 2009-10-01 Cellerant Therapeutics, Inc. Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof
EP2166021A1 (en) * 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
GB0823445D0 (en) * 2008-12-23 2009-01-28 Univ Surrey Biomarker
GB2472856B (en) 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
ES2566538T3 (es) 2011-01-19 2016-04-13 Cantargia Ab Anticuerpos anti-IL1RAP y su uso para el tratamiento de tumores sólidos
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
GB201413913D0 (en) 2014-08-06 2014-09-17 Cantargia Ab Novel antibodies and uses thereof
EP3313887A2 (en) 2015-06-26 2018-05-02 MAB Discovery GmbH Monoclonal anti-il-1racp antibodies
MA43164A (fr) 2015-11-02 2018-09-12 Janssen Pharmaceutica Nv Anticorps anti-il1rap, molécules bispécifiques de liaison à un antigène liant il1rap et cd3 et leurs utilisations
AU2017343784A1 (en) 2016-10-16 2019-08-29 Cantargia Ab Anti-IL1-RAP antibodies
WO2018071910A2 (en) 2016-10-16 2018-04-19 Cellerant Therapeutics, Inc. Anti-il1-rap antibodies

Also Published As

Publication number Publication date
RU2597831C2 (ru) 2016-09-20
CN103459424A (zh) 2013-12-18
DK3020730T3 (en) 2019-04-15
EP2665749B1 (en) 2016-01-13
EP3020730B1 (en) 2018-12-26
US20170081414A1 (en) 2017-03-23
ES2566538T3 (es) 2016-04-13
EP2665749A1 (en) 2013-11-27
US20140017167A1 (en) 2014-01-16
PL3020730T3 (pl) 2019-06-28
KR20140003550A (ko) 2014-01-09
WO2012098407A1 (en) 2012-07-26
US20210261674A1 (en) 2021-08-26
CA2824719C (en) 2020-06-02
US20180334506A1 (en) 2018-11-22
CN103459424B (zh) 2017-11-10
PL2665749T3 (pl) 2016-06-30
US11773174B2 (en) 2023-10-03
CA2824719A1 (en) 2012-07-26
BR112013018399A2 (pt) 2017-08-01
AU2012208379B2 (en) 2017-04-20
KR101989134B1 (ko) 2019-06-13
BR112013018399B1 (pt) 2022-11-01
EP3508498A1 (en) 2019-07-10
JP5940093B2 (ja) 2016-06-29
RU2013138439A (ru) 2015-02-27
DK2665749T3 (en) 2016-03-21
US9403906B2 (en) 2016-08-02
US10995144B2 (en) 2021-05-04
MX2013008375A (es) 2013-08-12
EP3020730A1 (en) 2016-05-18
JP2014511348A (ja) 2014-05-15
CN107929730A (zh) 2018-04-20
ES2714716T3 (es) 2019-05-29
US10005841B2 (en) 2018-06-26

Similar Documents

Publication Publication Date Title
MX354450B (es) Anticuerpos anti proteína accesoria del receptor de interleucina-1 y su uso para tratamiento en humanos.
IN2014CN03890A (es)
MX2012002163A (es) Agentes novedosos y usos de los mismos.
GB201020995D0 (en) Biological materials and uses thereof
WO2012058592A3 (en) Non-antagonistic egfr-binding molecules and immunoconjugates thereof
AU2015213336B2 (en) Novel conjugates of CC-1065 analogs and bifunctional linkers
PH12016501036A1 (en) Il-1 binding proteins
EA201490636A1 (ru) Сконструированные с помощью рнк t-клетки для лечения злокачественных новообразований
NZ709059A (en) Immunotherapy with binding agents
PH12016500395A1 (en) Cell penetrating conjugates and methods of use thereof
MX353352B (es) Anticuerpos anti-cd100 y metodos para su uso.
CR20110470A (es) Proteínas de union a il-17
MX370720B (es) Anticuerpos anti-gdf15.
EP2566890A4 (en) ANTI-PAI-1 ANTIBODIES AND METHOD FOR THEIR USE
MX2019009654A (es) Anticuerpos e inmunoconjugados del receptor 1 de folato y usos de los mismos.
TR201905909T4 (tr) Kanser tedavisi için anti-4-1bb antikorlarının ve adcc indükleyici antikorların kombinasyonları.
AU2010220421A8 (en) Antibodies against a proliferating inducing ligand (APRIL)
NZ609967A (en) Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
MX2014005800A (es) Mutaciones del receptor notch humano y su uso.
MX353476B (es) Anticuerpos anti-cxcl13 y metodos para usarlos.
PH12014501138A1 (en) Il-1 binding proteins
WO2012103360A3 (en) Wnt compositions and methods of use thereof
MX347247B (es) Agentes capaces de la activación de células t regulatorias cd4+cd25+ y su uso en el tratamiento de enfermedad.
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.

Legal Events

Date Code Title Description
FG Grant or registration